| 林菲菲,黄建平,杨军,张世正,谢尚任,周帆.宣肺清热方辅助治疗温州地区普通型新型冠状病毒肺炎的临床研究[J].浙江中西医结合杂志,2020,30(12): |
| 宣肺清热方辅助治疗温州地区普通型新型冠状病毒肺炎的临床研究 |
| Clinical study on the ordinary type of novel coronavirus pneumonia auxiliary treated by Xuanfei Qingre prescription in Wenzhou area. |
| 投稿时间：2020-04-27 修订日期：2020-09-21 |
| DOI： |
| 中文关键词: 宣肺清热方 新型冠状病毒肺炎 普通型 中西医结合 |
| 英文关键词:Xuanfei Qingre prescription novel coronavirus pneumonia the ordinary type combination of the western medicine and traditional chinese medicine |
| 基金项目:浙江省温州市新型冠状病毒肺炎疫情防控应急攻关项目（NO.ZY202004）：基于信息化系统构建的新型冠状病毒患者重症化机制及抗病毒治疗研究。 |
|
| 摘要点击次数: 538 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的：探讨宣肺清热方辅助治疗温州地区普通型新型冠状病毒肺炎患者的临床疗效和安全性。方法：选择普通型新冠肺炎患者82例，随机分为治疗组和对照组，每组41例，对照组予以西医常规治疗，治疗组在对照组基础上加用宣肺清热方。观察两组患者中医证候积分、中医证候疗效、肺部病灶吸收疗效、实验室指标、症状消失天数、首次痰核酸转阴天数、住院天数、住院费用、发生重型/危重型的比例、不良反应发生情况。结果：经过治疗后，治疗组较对照组咳嗽积分[(0.80±1.35)分比（1.68±1.51）分]、中医证候总积分[（1.17±1.63）分比（3.00±2.77）分]下降明显，差异有统计学意义（P<0.05）。治疗组较对照组发热、咳嗽、乏力、咽痛、胸闷、纳差、腹泻所有症状消失天数[（11.85±3.70）天比（15.00±6.51）天]、首次痰核酸转阴天数[（18.83±5.79）天比（22.41±8.48）天]、住院天数[（22.20±5.21）天比（25.41±7.81）天]、住院费用[（14014.47±5638.39）元比（20267.63±9883.74）元]少，差异均有统计学意义（P<0.05）。治疗组较对照组中医证候有效率[（97.56%）比（78.05%）]、肺部病灶吸收有效率[（97.56%）比（85.37%）]高，差异均有统计学意义（P<0.05）。治疗后，治疗组较对照组C-反应蛋白正常例数[（36）例比（27）例]、谷丙转氨酶正常例数[（37）例比（29）例]、谷草转氨酶正常例数[（40）比（33）例]、血沉正常例数[（18）例比（9）例]高，差异有统计学意义（P<0.05）。治疗组无患者发展为重型，对照组有2例患者发展为重型，两组均无患者发展为危重型，无不良反应，差异无统计学意义(P>0.05)。结论：温州地区普通型新冠肺炎患者辅以宣肺清热方，可改善患者症状，加速肺部病灶吸收，减轻机体炎症反应，改善肝功能，缩短痰核酸转阴天数、住院天数，减少住院费用，无不良反应。 |
| 英文摘要: |
| Objective: To investigate the clinical efficacy and safety on the ordinary type of novel coronavirus pneumonia patients auxiliary treated by Xuanfei Qingre prescription in Wenzhou area. Method:To selecte 82 patients with ordinary type of coronavirus pneumonia randomly divided into treatment group and control group, 41 cases in each group. The control group was given routine western medicine treatment, while the treatment group was additionally given Xuanfei Qingre prescription on the basis of the control group. To observe the TCM syndrome score, TCM syndrome efficacy, lung focus absorption efficacy, laboratory indicators, symptom disappearance days, the first time of sputum nucleic acid negative days, hospitalization days, hospitalization expenses, proportion of heavy/dangerous, occurrence of adverse reactions. Result: After treatment, the cough score[(0.80±1.35)vs（1.68±1.51）] and TCM syndrome total score[（1.17±1.63）vs（3.00±2.77）] in the treatment group decreased significantly compared with the control group, the difference is statistically significant（P <0.05）. Days of disappearance of fever, cough, fatigue, sore throat, chest distress, poor feeling and diarrhea[（11.85±3.70）vs（15.00±6.51）], the first time of sputum nucleic acid negative days[（18.83±5.79）vs（22.41±8.48）], hospitalization days[（22.20±5.21）vs（25.41±7.81）], hospitalization expenses[（14014.47±5638.39）vs（20267.63±9883.74）] in the treatment group were shorter than those in the control group, the effective rate of TCM syndromes[（97.56%）vs（78.05%）] and absorption of pulmonary lesions[（97.56%）vs（85.37%）] in the treatment group was higher than that in the control group, the difference is statistically significant（P <0.05）.After treatment, the number of normal cases of CRP[（36）vs（27）], ALT[（37）vs（29）], AST[（40）vs（33）] and ESR[（18）vs（9）] in the treatment group was higher than that in the control group，the difference is statistically significant（P <0.05）. No patient in the treatment group developed to severe, 2 patients in the control group developed to severe, no patient in both groups developed to severe, no adverse reactions, the difference was not statistically significant（P>0.05）. Conclusion: The Wenzhou the ordinary type of novel coronavirus pneumonia patients auxiliary treated by Xuanfei Qingre prescription, can improve the symptoms of patients, accelerate the absorption of lung lesions, reduce inflammation and improve liver function, shorten the days of sputum nucleic acid conversion, hospitalization days, reduce hospitalization expenses and have no adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
